Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. HON
4. KBH
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. QCOM

Go back to Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

December 6, 2020 3:00 PM EST

-- 85 Percent of Patients Responded to a Single Infusion of Yescarta, Including 74 Percent of Patients Achieving Complete Response --

-- ZUMA-12 Results Are First to Support Potential of CAR T in Earlier Lines of Therapy --

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced results from the interim analysis of ZUMA-12, a multicenter, open-label, single-arm Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). After a single infusion of Yescarta, 85... More